Holen Sie sich die Stockscreener-App
3.90
8.35%
-0.35
Handel nachbörslich:
3.87
-0.03
-0.77%
Schlusskurs vom Vortag:
$4.25
Offen:
$4.16
24-Stunden-Volumen:
1.65M
Relative Volume:
0.67
Marktkapitalisierung:
$333.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-36.95M
KGV:
-4.6429
EPS:
-0.84
Netto-Cashflow:
$-33.46M
1W Leistung:
-17.48%
1M Leistung:
-0.89%
6M Leistung:
+108.29%
1J Leistung:
-46.28%
1-Tages-Spanne:
$3.875
$4.21
1-Wochen-Bereich:
$3.875
$4.99
52-Wochen-Spanne:
$1.61
$9.50
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Firmenname
Larimar Therapeutics Inc
Sektor
Branche
Telefon
844-511-9056
Adresse
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Vergleichen Sie LRMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.90 | 373.17M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-29 | Eingeleitet | Truist | Buy |
| 2024-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-03 | Eingeleitet | Wedbush | Outperform |
| 2024-10-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-03 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-19 | Eingeleitet | Guggenheim | Buy |
| 2022-02-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-02-01 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Larimar Therapeutics Inc Aktie (LRMR) Neueste Nachrichten
Larimar Therapeutics, Inc. Securities Lawsuit Investigation - Claim Depot
Is Larimar Therapeutics Inc. (ZA71) stock worth buying before Fed actionJuly 2025 Highlights & Low Risk Entry Point Tips - newser.com
Larimar Therapeutics Reports Promising Clinical Data Update - TipRanks
Larimar Therapeutics, Inc. Updates on Nomlabofusp Development - TradingView
What candlestick patterns are forming on Larimar Therapeutics Inc.Earnings Trend Report & Daily Oversold Stock Bounce Ideas - newser.com
How Larimar Therapeutics Inc. (ZA71) stock compares with top peersMarket Activity Recap & Precise Entry and Exit Recommendations - newser.com
Market reaction to Larimar Therapeutics Inc.’s recent newsMarket Performance Report & Free Safe Entry Trade Signal Reports - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.LRMR - PR Newswire
Multi factor analysis applied to Larimar Therapeutics Inc.2025 Price Momentum & Community Driven Trade Alerts - newser.com
Is Larimar Therapeutics Inc. stock poised for growthQuarterly Profit Summary & High Accuracy Investment Entry Signals - newser.com
Real time breakdown of Larimar Therapeutics Inc. stock performanceQuarterly Profit Report & Risk Managed Investment Strategies - newser.com
Larimar Therapeutics (NASDAQ:LRMR) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Intraday pattern recognizer results for Larimar Therapeutics Inc.2025 Buyback Activity & Consistent Profit Focused Trading Strategies - newser.com
How to forecast Larimar Therapeutics Inc. trends using time seriesQuarterly Profit Review & Stock Portfolio Risk Control - newser.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Volatility clustering patterns for Larimar Therapeutics Inc.July 2025 PostEarnings & Free Real-Time Volume Trigger Notifications - newser.com
What MACD and RSI say about Larimar Therapeutics Inc.Trade Ideas & Verified Stock Trade Ideas - newser.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Larimar announces 25 mg, 50 mg data from OL study of nomlabofusp - MSN
Citizens JMP Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
Why Larimar Therapeutics Inc. (ZA71) stock fits value portfoliosDip Buying & Short-Term Trading Alerts - newser.com
Using Python tools to backtest Larimar Therapeutics Inc. strategiesJuly 2025 Pullbacks & Risk Adjusted Buy/Sell Alerts - newser.com
Can you recover from losses in Larimar Therapeutics Inc.2025 Price Momentum & Risk Controlled Stock Alerts - newser.com
Larimar Reports Positive Long-Term Data on Nomlabofusp in Friedreich’s Ataxia - MyChesCo
What’s next for Larimar Therapeutics Inc. stock priceEarnings Overview Report & Accurate Technical Buy Alerts - newser.com
What analysts say about Larimar Therapeutics Inc stockDouble Top/Bottom Patterns & Low Risk Trading Portfolio - earlytimes.in
Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment? - Yahoo Finance
Why Larimar Therapeutics (LRMR) Is Up After Positive Long-Term Results for Friedreich's Ataxia Therapy - Sahm
Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $21.00 by Analysts at Oppenheimer - Defense World
Why ETFs are accumulating Larimar Therapeutics Inc. (ZA71) stockDividend Hike & Real-Time Stock Movement Alerts - newser.com
Oppenheimer Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Oppenheimer Lowers Larimar Therapeutics (LRMR) Price Target to $21 | LRMR Stock News - GuruFocus
Equities Analysts Issue Forecasts for LRMR FY2027 Earnings - MarketBeat
Is now a turning point for Larimar Therapeutics Inc.2025 Technical Overview & High Accuracy Trade Alerts - newser.com
What analysts say about CTVA stockCandlestick Pattern Analysis & Rapid Capital Appreciation - earlytimes.in
Baird Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $7 - 富途牛牛
Wedbush Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq
Anaphylaxis drives Larimar’s setback, weak efficacy behind MoonLake’s: Clinical Report - BioCentury
Navigating Larimar’s Anaphylaxis Storm: Robust FA Data Presents Risk-Reward Opportunity (NASDAQ:LRMR) - Seeking Alpha
LRMR Analyst Rating Update: Price Target Lowered by Wedbush | LR - GuruFocus
Larimar Therapeutics (NASDAQ:LRMR) Given New $11.00 Price Target at Wedbush - MarketBeat
LRMR: Baird Maintains Rating but Lowers Price Target to $7.00 | - GuruFocus
Wedbush Cuts Price Target on Larimar Therapeutics to $11 From $15, Keeps Outperform Rating - MarketScreener
Baird Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq
Finanzdaten der Larimar Therapeutics Inc-Aktie (LRMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):